Metformin
Sulfonylurea Compounds
Diabetes Mellitus, Type 2
Polycystic Ovary Syndrome
AMP-Activated Protein Kinases
Phenformin
Thiazolidinediones
Acidosis, Lactic
Adenylate Kinase
Clomiphene
Hemoglobin A, Glycosylated
Insulin
Aminoimidazole Carboxamide
Drug Therapy, Combination
Insulin Resistance
Organic Cation Transport Proteins
Ribonucleotides
Dipeptidyl-Peptidase IV Inhibitors
The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. (1/1410)
OBJECTIVE: To determine whether metformin. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while body weight is maintained. Also we aimed to see whether the reduction in insulin levels attenuates the activity of adrenal P450c17alpha enzyme in patients with PCOS. DESIGN: We investigated the 17-hydroxyprogesterone (17-OHP) and androstenedione responses to ACTH, insulin responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after metformin therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was demonstrated by an OGTT and results were compared with those of 10 healthy women. Insulin sensitivity was measured by the rate of endogenous glucose disposal after i.v. bolus injection of insulin. 17-OHP and androstenedione responses to ACTH were measured in all the women with PCOS and the normal women. RESULTS: Women with PCOS were hyperinsulinemic (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more hirsute (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to metformin. CONCLUSIONS: PCOS is characterized by hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance. It seems that there is no direct relationship between insulin resistance and adrenal P450c17alpha enzyme dysregulation. (+info)The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. (2/1410)
The Diabetes Prevention Program is a randomized clinical trial testing strategies to prevent or delay the development of type 2 diabetes in high-risk individuals with elevated fasting plasma glucose concentrations and impaired glucose tolerance. The 27 clinical centers in the U.S. are recruiting at least 3,000 participants of both sexes, approximately 50% of whom are minority patients and 20% of whom are > or = 65 years old, to be assigned at random to one of three intervention groups: an intensive lifestyle intervention focusing on a healthy diet and exercise and two masked medication treatment groups--metformin or placebo--combined with standard diet and exercise recommendations. Participants are being recruited during a 2 2/3-year period, and all will be followed for an additional 3 1/3 to 5 years after the close of recruitment to a common closing date in 2002. The primary outcome is the development of diabetes, diagnosed by fasting or post-challenge plasma glucose concentrations meeting the 1997 American Diabetes Association criteria. The 3,000 participants will provide 90% power to detect a 33% reduction in an expected diabetes incidence rate of at least 6.5% per year in the placebo group. Secondary outcomes include cardiovascular disease and its risk factors; changes in glycemia, beta-cell function, insulin sensitivity, obesity, diet, physical activity, and health-related quality of life; and occurrence of adverse events. A fourth treatment group--troglitazone combined with standard diet and exercise recommendations--was included initially but discontinued because of the liver toxicity of the drug. This randomized clinical trial will test the possibility of preventing or delaying the onset of type 2 diabetes in individuals at high risk. (+info)Efficacy of metformin in the treatment of NIDDM. Meta-analysis. (3/1410)
OBJECTIVE: The results differ concerning randomized controlled trials of the effects of metformin on blood glucose regulation and body weight. To get a systematic overview, a meta-analysis of the efficacy of metformin was performed by comparing metformin with placebo and sulfonylurea. RESEARCH DESIGN AND METHODS: All randomized controlled trials published since 1957 were selected by searching the Current List of Medical Literature, Cumulated Index Medicus, Medline, and Embase, Meta-analysis was performed calculating weighted mean difference (WMD) of fasting blood glucose, glycosylated hemoglobin, and body weight. RESULTS: Nine randomized controlled trials comparing metformin with placebo and ten comparing metformin with sulfonylurea were identified. The WMD between metformin and placebo after treatment for fasting blood glucose was -2.0 mmol/l (95% CI -2.4 to -1.7) and for glycosylated hemoglobin -0.9% (95% CI -1.1 to -0.7). Body weight WMD was not significant after treatment. Sulfonylurea and metformin lowered blood glucose and glycosylated hemoglobin equally, while there was a significant WMD of body weight (-2.9 kg [95% CI -4.4 to -1.1]) because of a 1.7-kg mean increase after sulfonylurea and a 1.2-kg mean decrease after metformin. CONCLUSIONS: Metformin lowers blood glucose and glycosylated hemoglobin significantly, compared with placebo. Metformin and sulfonylurea have an equal effect on fasting blood glucose and glycosylated hemoglobin, but the body weight is significantly lower after metformin compared with sulfonylurea treatment because of an increase in body weight after sulfonylurea treatment. (+info)First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. (4/1410)
OBJECTIVE: To assess adherence to prescribing guidelines, continuation rates, population effects on glycemic control, and occurrence of lactic acidosis during the first 20 months of the availability of metformin in a large health maintenance organization. RESEARCH DESIGN AND METHODS: A retrospective cohort study was performed in the 90,000-member diabetes registry of Kaiser Permanente, northern California. Principal study measures were the proportions of patients started on metformin who met prescribing guidelines (previously on sulfonylureas, HbA1c, obesity, creatinine), the change in HbA1c at 6 months after starting metformin, and hospitalization rates for lactic acidosis. RESULTS: A total of 9,875 patients received metformin during this interval. At least 74% were previously treated with sulfonylureas alone, 81% had baseline HbA1c > or = 8.5%, 71% were obese, and 99% had a serum creatinine < or = 1.5 mg/dl. Among patients on sulfonylureas at baseline, those starting metformin had significantly lower HbA1c levels 6 months later than those not started, after adjustment for age, sex, and the higher baseline levels in those started (adjusted difference: 0.5%, P < 0.0001). Patients starting metformin as initial monotherapy also improved significantly, but patients previously treated with insulin (with or without sulfonyl-ureas) had slightly higher follow-up HbA1c levels than similar patients not starting metformin. Continuation of metformin at 12 months was significantly higher for patients previously treated with sulfonylureas than other groups. One probable case of lactic acidosis was identified during 4,502 person-years on metformin. CONCLUSIONS: Adherence to prescribing guidelines was relatively high during metformin's first 20 months of availability. Glycemic control improved substantially for patients previously treated with sulfonylureas. Lactic acidosis was rare. (+info)Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. (5/1410)
OBJECTIVE: To compare the effect of repaglinide in combination with metformin with monotherapy of each drug on glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 83 patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin were enrolled in this multicenter, double-blind trial. Subjects were randomized to continue with their prestudy dose of metformin (n = 27), to continue with their prestudy dose of metformin with the addition of repaglinide (n = 27), or to receive repaglinide alone (n = 29). For patients receiving repaglinide, the optimal dose was determined during a 4- to 8-week titration and continued for a 3-month maintenance period. RESULTS: In subjects receiving combined therapy, HbA1c was reduced by 1.4 +/- 0.2%, from 8.3 to 6.9% (P = 0.0016) and fasting plasma glucose by 2.2 mmol/l (P = 0.0003). No significant changes were observed in subjects treated with either repaglinide or metformin monotherapy in HbA1c (0.4 and 0.3% decrease, respectively) or fasting plasma glucose (0.5 mmol/l increase and 0.3 mmol/l decrease respectively). Subjects receiving repaglinide either alone or in combination with metformin, had an increase in fasting levels of insulin between baseline and the end of the trial of 4.04 +/- 1.56 and 4.23 +/- 1.50 mU/l, respectively (P < 0.02). Gastrointestinal adverse events were common in the metformin group. An increase in body weight occurred in the repaglinide and combined therapy groups (2.4 +/- 0.5 and 3.0 +/- 0.5 kg, respectively; P < 0.05). CONCLUSIONS: Combined metformin and repaglinide therapy resulted in superior glycemic control compared with repaglinide or metformin monotherapy in patients with type 2 diabetes whose glycemia had not been well controlled on metformin alone. Repaglinide monotherapy was as effective as metformin monotherapy. (+info)An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. (6/1410)
Recently there has been growing interest in the effects of antioxidants on insulin activity. In the present study, we investigated the effect of metformin on free radical activity and insulin sensitivity in high fructose-fed rats, a diet that leads to insulin resistance. The animals were divided into four groups (n = 16 per group; experiment duration = 6 weeks): the control (C) group received a standard diet; the control metformin (CM) group was fed a control diet and received metformin (200 mg x kg(-1) x day(-1) in water); the fructose control (FT) group was fed a diet in which fructose composed 56.8% of the total carbohydrates; and the fructose metformin (FM) group received high-fructose diet and metformin (200 mg x kg(-1) x day(-1) in water). The glucose clamp technique was used to determine insulin sensitivity in eight animals per group. Metabolic and oxidative stress parameters were measured in the remaining rats. In the FT rats, insulin resistance, lower red cell CuZn superoxide dismutase activity and lower blood reduced glutathione were observed. Metformin treatment improved both the insulin activity and the antioxidant defense system. In the CM group, metformin had no effect on metabolic parameters, but improved red cell antioxidant enzyme activities and the blood GSH level, which suggests that it has an antioxidant activity independent of its effect on insulin activity. (+info)Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. (7/1410)
Metformin, an antihyperglycemic agent used for treatment of type 2 diabetes mellitus, lowers blood pressure in humans and experimental animals. We recently demonstrated that short-term administration of metformin may lower blood pressure by reducing sympathetic neural outflow. The present studies were initiated to determine whether long-term administration of metformin blunts salt-induced hypertension, a condition characterized by elevated sympathetic activity. Male spontaneously hypertensive rats, in which radiotelemeters had been implanted for continuous monitoring of heart rate and blood pressure, were randomly assigned to groups that received vehicle (drinking water) or metformin (500 mg/kg per day) and ate a normal 0.3% NaCl diet and to groups that received vehicle or metformin and ate a high 8.0% NaCl diet for a period of 4 weeks. Although metformin did not affect blood pressure in the animals that ate the normal-salt diet (vehicle, 130+/-3 mm Hg; metformin, 133+/-5 mm Hg; mean+/-SEM), drug treatment blunted the rise in pressure caused by a high-salt diet (vehicle, 153+/-4 mm Hg; metformin, 140+/-5 mm Hg; P<0.001). In agreement, during direct pressure recordings in anesthetized rats, the animals that ate the high-salt diet had higher pressures (136+/-13 mm Hg) than those in the control (98+/-5 mm Hg, P<0.01), metformin (100+/-7 mm Hg, P<0.01), and metformin/high-salt groups (92+/-3 mm Hg, P<0.01). Finally, metformin lowered heart rate in rats that ate the normal- and high-salt diets (310+/-3 and 305+/-4 bpm) compared with rats that ate normal- and high-salt diets given vehicle (332+/-3 and 324+/-2 bpm, P<0.01). These data indicate that the chronic depressor actions of metformin are enhanced in animals with hypertension exacerbated by a high-salt diet. (+info)Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. (8/1410)
To better define the modifications of liver gluconeogenesis and citric acid cycle, or Krebs' cycle, activity induced by insulin deficiency and the effects of metformin on these abnormalities, we infused livers isolated from postabsorptive or starved normal and streptozotocin-induced diabetic rats with pyruvate and lactate (labeled with [3-13C]lactate) with or without the simultaneous infusion of metformin. Lactate and pyruvate uptake and glucose production were calculated. The 13C-labeling pattern of liver glutamate was used to calculate, according to Magnusson's model, the relative fluxes through Krebs' cycle and gluconeogenesis. These relative fluxes were converted into absolute values using substrate balances. In normal rats, starvation increased gluconeogenesis, the flux through pyruvate carboxylase-phosphoenolpyruvate carboxykinase (PC-PEPCK), and the ratio of PC to pyruvate dehydrogenase (PDH) flux (P < 0.05); metformin induced only a moderate decrease in the PC:PDH ratio. Livers from postabsorptive diabetic rats had increased lactate and pyruvate uptakes (P < 0.05); their metabolic fluxes resembled those of starved control livers, with increased gluconeogenesis and flux through PC-PEPCK. Starvation induced no further modifications in the diabetic group. Metformin decreased glucose output from the liver of starved diabetic rats (P < 0.05). The flux through PC-PEPCK and also pyruvate kinase were decreased (P < 0.05) by metformin in both groups of diabetic rats. In conclusion, insulin deficiency increased in this model of diabetes gluconeogenesis through enhanced uptake of substrate and increased flux through PC-PEPCK; metformin decreased glucose production by reducing the flux through PC-PEPCK. (+info)Metformin is a type of biguanide antihyperglycemic agent used primarily in the treatment of type 2 diabetes mellitus. It works by decreasing glucose production in the liver, reducing glucose absorption in the gut, and increasing insulin sensitivity in muscle and fat tissue. By lowering both basal and postprandial plasma glucose levels, metformin helps to control blood sugar levels and improve glycemic control. It is also used off-label for various other indications such as polycystic ovary syndrome (PCOS) and gestational diabetes. Common side effects include diarrhea, nausea, vomiting, and abdominal discomfort. Lactic acidosis is a rare but serious side effect that requires immediate medical attention.
Hypoglycemic agents are a class of medications that are used to lower blood glucose levels in the treatment of diabetes mellitus. These medications work by increasing insulin sensitivity, stimulating insulin release from the pancreas, or inhibiting glucose production in the liver. Examples of hypoglycemic agents include sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. It's important to note that the term "hypoglycemic" refers to a condition of abnormally low blood glucose levels, but in this context, the term is used to describe agents that are used to treat high blood glucose levels (hyperglycemia) associated with diabetes.
Sulfonylurea compounds are a group of medications used in the management of type 2 diabetes. They work by stimulating the release of insulin from the pancreas, thereby lowering blood glucose levels. These compounds bind to specific receptors on the beta cells of the pancreas, which triggers the release of insulin.
Examples of sulfonylurea compounds include glipizide, glyburide, and glimepiride. It's important to note that these medications can cause hypoglycemia (low blood sugar) if not properly monitored and dosed. They are often used in combination with other medications, such as metformin, to achieve optimal blood glucose control.
As with any medication, sulfonylurea compounds should be taken under the supervision of a healthcare provider, who can monitor their effectiveness and potential side effects.
Diabetes Mellitus, Type 2 is a metabolic disorder characterized by high blood glucose (or sugar) levels resulting from the body's inability to produce sufficient amounts of insulin or effectively use the insulin it produces. This form of diabetes usually develops gradually over several years and is often associated with older age, obesity, physical inactivity, family history of diabetes, and certain ethnicities.
In Type 2 diabetes, the body's cells become resistant to insulin, meaning they don't respond properly to the hormone. As a result, the pancreas produces more insulin to help glucose enter the cells. Over time, the pancreas can't keep up with the increased demand, leading to high blood glucose levels and diabetes.
Type 2 diabetes is managed through lifestyle modifications such as weight loss, regular exercise, and a healthy diet. Medications, including insulin therapy, may also be necessary to control blood glucose levels and prevent long-term complications associated with the disease, such as heart disease, nerve damage, kidney damage, and vision loss.
Polycyctic Ovary Syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by the presence of hyperandrogenism (excess male hormones), ovulatory dysfunction, and polycystic ovaries. The Rotterdam criteria are commonly used for diagnosis, which require at least two of the following three features:
1. Oligo- or anovulation (irregular menstrual cycles)
2. Clinical and/or biochemical signs of hyperandrogenism (e.g., hirsutism, acne, or high levels of androgens in the blood)
3. Polycystic ovaries on ultrasound examination (presence of 12 or more follicles measuring 2-9 mm in diameter, or increased ovarian volume >10 mL)
The exact cause of PCOS remains unclear, but it is believed to involve a combination of genetic and environmental factors. Insulin resistance and obesity are common findings in women with PCOS, which can contribute to the development of metabolic complications such as type 2 diabetes, dyslipidemia, and cardiovascular disease.
Management of PCOS typically involves a multidisciplinary approach that includes lifestyle modifications (diet, exercise, weight loss), medications to regulate menstrual cycles and reduce hyperandrogenism (e.g., oral contraceptives, metformin, anti-androgens), and fertility treatments if desired. Regular monitoring of metabolic parameters and long-term follow-up are essential for optimal management and prevention of complications.
AMP-activated protein kinases (AMPK) are a group of heterotrimeric enzymes that play a crucial role in cellular energy homeostasis. They are composed of a catalytic subunit (α) and two regulatory subunits (β and γ). AMPK is activated under conditions of low energy charge, such as ATP depletion, hypoxia, or exercise, through an increase in the AMP:ATP ratio.
Once activated, AMPK phosphorylates and regulates various downstream targets involved in metabolic pathways, including glycolysis, fatty acid oxidation, and protein synthesis. This results in the inhibition of energy-consuming processes and the promotion of energy-producing processes, ultimately helping to restore cellular energy balance.
AMPK has been implicated in a variety of physiological processes, including glucose and lipid metabolism, autophagy, mitochondrial biogenesis, and inflammation. Dysregulation of AMPK activity has been linked to several diseases, such as diabetes, obesity, cancer, and neurodegenerative disorders. Therefore, AMPK is an attractive target for therapeutic interventions in these conditions.
Phenformin is a medication that was previously used to treat type 2 diabetes. It belongs to a class of drugs called biguanides, which work to decrease the amount of glucose produced by the liver and increase the body's sensitivity to insulin. However, phenformin was associated with an increased risk of lactic acidosis, a potentially life-threatening condition characterized by an excessive buildup of lactic acid in the bloodstream. As a result, it is no longer available or recommended for use in most countries, including the United States.
Thiazolidinediones are a class of medications used to treat type 2 diabetes. They work by increasing the body's sensitivity to insulin, which helps to control blood sugar levels. These drugs bind to peroxisome proliferator-activated receptors (PPARs), specifically PPAR-gamma, and modulate gene expression related to glucose metabolism and lipid metabolism.
Examples of thiazolidinediones include pioglitazone and rosiglitazone. Common side effects of these medications include weight gain, fluid retention, and an increased risk of bone fractures. They have also been associated with an increased risk of heart failure and bladder cancer, which has led to restrictions or withdrawal of some thiazolidinediones in various countries.
It is important to note that thiazolidinediones should be used under the close supervision of a healthcare provider and in conjunction with lifestyle modifications such as diet and exercise.
Lactic acidosis is a medical condition characterized by an excess accumulation of lactic acid in the body. Lactic acid is a byproduct produced in the muscles and other tissues during periods of low oxygen supply or increased energy demand. Under normal circumstances, lactic acid is quickly metabolized and cleared from the body. However, when the production of lactic acid exceeds its clearance, it can lead to a state of acidosis, where the pH of the blood becomes too acidic.
Lactic acidosis can be caused by several factors, including:
* Prolonged exercise or strenuous physical activity
* Severe illness or infection
* Certain medications, such as metformin and isoniazid
* Alcoholism
* Hypoxia (low oxygen levels) due to lung disease, heart failure, or anemia
* Inherited metabolic disorders that affect the body's ability to metabolize lactic acid
Symptoms of lactic acidosis may include rapid breathing, fatigue, muscle weakness, nausea, vomiting, and abdominal pain. Severe cases can lead to coma, organ failure, and even death. Treatment typically involves addressing the underlying cause of the condition and providing supportive care, such as administering intravenous fluids and bicarbonate to help restore normal pH levels.
Blood glucose, also known as blood sugar, is the concentration of glucose in the blood. Glucose is a simple sugar that serves as the main source of energy for the body's cells. It is carried to each cell through the bloodstream and is absorbed into the cells with the help of insulin, a hormone produced by the pancreas.
The normal range for blood glucose levels in humans is typically between 70 and 130 milligrams per deciliter (mg/dL) when fasting, and less than 180 mg/dL after meals. Levels that are consistently higher than this may indicate diabetes or other metabolic disorders.
Blood glucose levels can be measured through a variety of methods, including fingerstick blood tests, continuous glucose monitoring systems, and laboratory tests. Regular monitoring of blood glucose levels is important for people with diabetes to help manage their condition and prevent complications.
Adenylate kinase is an enzyme (EC 2.7.4.3) that catalyzes the reversible transfer of a phosphate group between adenine nucleotides, specifically between ATP and AMP to form two ADP molecules. This reaction plays a crucial role in maintaining the energy charge of the cell by interconverting these important energy currency molecules.
The general reaction catalyzed by adenylate kinase is:
AMP + ATP ↔ 2ADP
This enzyme is widely distributed in various organisms and tissues, including mammalian cells. In humans, there are several isoforms of adenylate kinase, located in different cellular compartments such as the cytosol, mitochondria, and nucleus. These isoforms have distinct roles in maintaining energy homeostasis and protecting cells under stress conditions. Dysregulation of adenylate kinase activity has been implicated in several pathological processes, including neurodegenerative diseases, ischemia-reperfusion injury, and cancer.
Clomiphene is a medication that is primarily used to treat infertility in women. It is an ovulatory stimulant, which means that it works by stimulating the development and release of mature eggs from the ovaries (a process known as ovulation). Clomiphene is a selective estrogen receptor modulator (SERM), which means that it binds to estrogen receptors in the body and blocks the effects of estrogen in certain tissues, while enhancing the effects of estrogen in others.
In the ovary, clomiphene works by blocking the negative feedback effect of estrogen on the hypothalamus and pituitary gland, which results in an increase in the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones stimulate the growth and development of ovarian follicles, which contain eggs. As the follicles grow and mature, they produce increasing amounts of estrogen, which eventually triggers a surge in LH that leads to ovulation.
Clomiphene is typically taken orally for 5 days, starting on the 3rd, 4th, or 5th day of the menstrual cycle. The dosage may be adjusted based on the patient's response to treatment. Common side effects of clomiphene include hot flashes, mood changes, breast tenderness, and ovarian hyperstimulation syndrome (OHSS), which is a potentially serious complication characterized by the enlargement of the ovaries and the accumulation of fluid in the abdomen.
It's important to note that clomiphene may not be suitable for everyone, and its use should be carefully monitored by a healthcare provider. Women with certain medical conditions, such as liver disease, thyroid disorders, or uterine fibroids, may not be able to take clomiphene. Additionally, women who become pregnant while taking clomiphene have an increased risk of multiple pregnancies (e.g., twins or triplets), which can pose additional risks to both the mother and the fetuses.
Female fertility agents are medications or treatments that are used to enhance or restore female fertility. They can work in various ways such as stimulating ovulation, improving the quality of eggs, facilitating the implantation of a fertilized egg in the uterus, or addressing issues related to the reproductive system.
Some examples of female fertility agents include:
1. Clomiphene citrate (Clomid, Serophene): This medication stimulates ovulation by causing the pituitary gland to release more follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
2. Gonadotropins: These are hormonal medications that contain FSH and LH, which stimulate the ovaries to produce mature eggs. Examples include human menopausal gonadotropin (hMG) and follicle-stimulating hormone (FSH).
3. Letrozole (Femara): This medication is an aromatase inhibitor that can be used off-label to stimulate ovulation in women who do not respond to clomiphene citrate.
4. Metformin (Glucophage): This medication is primarily used to treat type 2 diabetes, but it can also improve fertility in women with polycystic ovary syndrome (PCOS) by regulating insulin levels and promoting ovulation.
5. Bromocriptine (Parlodel): This medication is used to treat infertility caused by hyperprolactinemia, a condition characterized by high levels of prolactin in the blood.
6. Assisted reproductive technologies (ART): These include procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and gamete intrafallopian transfer (GIFT). They involve manipulating eggs and sperm outside the body to facilitate fertilization and implantation.
It is important to consult with a healthcare provider or reproductive endocrinologist to determine the most appropriate fertility agent for individual needs, as these medications can have side effects and potential risks.
Glycosylated Hemoglobin A, also known as Hemoglobin A1c or HbA1c, is a form of hemoglobin that is bound to glucose. It is formed in a non-enzymatic glycation reaction with glucose in the blood. The amount of this hemoglobin present in the blood is proportional to the average plasma glucose concentration over the previous 8-12 weeks, making it a useful indicator for monitoring long-term blood glucose control in people with diabetes mellitus.
In other words, HbA1c reflects the integrated effects of glucose regulation over time and is an important clinical marker for assessing glycemic control and risk of diabetic complications. The normal range for HbA1c in individuals without diabetes is typically less than 5.7%, while a value greater than 6.5% is indicative of diabetes.
Glipizide is an oral anti-diabetic medication belonging to the sulfonylurea class. It is used in the management of type 2 diabetes mellitus, by stimulating the release of insulin from the pancreas and reducing glucose production in the liver. Glipizide works by binding to specific receptors on the beta cells of the pancreas, leading to an increase in intracellular calcium levels and ultimately resulting in insulin secretion.
The medical definition of Glipizide is: "A second-generation sulfonylurea used in the treatment of type 2 diabetes mellitus. It acts by binding to specific receptors on the beta cells of the pancreas, leading to an increase in intracellular calcium levels and insulin secretion."
It is important to note that Glipizide should be used with caution in patients with impaired kidney or liver function, as well as those who are at risk for hypoglycemia. Regular monitoring of blood glucose levels is necessary during treatment with Glipizide to ensure safe and effective use.
Insulin is a hormone produced by the beta cells of the pancreatic islets, primarily in response to elevated levels of glucose in the circulating blood. It plays a crucial role in regulating blood glucose levels and facilitating the uptake and utilization of glucose by peripheral tissues, such as muscle and adipose tissue, for energy production and storage. Insulin also inhibits glucose production in the liver and promotes the storage of excess glucose as glycogen or triglycerides.
Deficiency in insulin secretion or action leads to impaired glucose regulation and can result in conditions such as diabetes mellitus, characterized by chronic hyperglycemia and associated complications. Exogenous insulin is used as a replacement therapy in individuals with diabetes to help manage their blood glucose levels and prevent long-term complications.
Aminoimidazole carboxamide is a compound that is involved in the metabolic pathways of nucleotide synthesis in cells. It is also known as AICA ribonucleotide, and is a precursor to an important energy molecule in the body called adenosine triphosphate (ATP).
In medical terms, aminoimidazole carboxamide is sometimes used as a research tool to study cellular metabolism and has been investigated for its potential therapeutic use in various conditions such as neurodegenerative disorders and ischemia-reperfusion injury. However, it is not commonly used as a medication in clinical practice.
Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.
In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:
1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.
Examples of combination drug therapy include:
1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.
When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.
Insulin resistance is a condition in which the body's cells become less responsive to insulin, a hormone produced by the pancreas that regulates blood sugar levels. In response to this decreased sensitivity, the pancreas produces more insulin to help glucose enter the cells. However, over time, the pancreas may not be able to keep up with the increased demand for insulin, leading to high levels of glucose in the blood and potentially resulting in type 2 diabetes, prediabetes, or other health issues such as metabolic syndrome, cardiovascular disease, and non-alcoholic fatty liver disease. Insulin resistance is often associated with obesity, physical inactivity, and genetic factors.
Organic cation transport proteins (OCTs) are a group of membrane transporters that facilitate the movement of organic cations across biological membranes. These transporters play an essential role in the absorption, distribution, and elimination of various endogenous and exogenous substances, including drugs and toxins.
There are four main types of OCTs, namely OCT1, OCT2, OCT3, and OCTN1 (also known as novel organic cation transporter 1 or OCT6). These proteins belong to the solute carrier (SLC) family, specifically SLC22A.
OCTs have a broad substrate specificity and can transport various organic cations, such as neurotransmitters (e.g., serotonin, dopamine, histamine), endogenous compounds (e.g., creatinine, choline), and drugs (e.g., metformin, quinidine, morphine). The transport process is typically sodium-independent and can occur in both directions, depending on the concentration gradient of the substrate.
OCTs are widely expressed in various tissues, including the liver, kidney, intestine, brain, heart, and placenta. Their expression patterns and functions vary among different OCT types, contributing to their diverse roles in physiology and pharmacology. Dysfunction of OCTs has been implicated in several diseases, such as drug toxicity, neurodegenerative disorders, and cancer.
In summary, organic cation transport proteins are membrane transporters that facilitate the movement of organic cations across biological membranes, playing crucial roles in the absorption, distribution, and elimination of various substances, including drugs and toxins.
Ribonucleotides are organic compounds that consist of a ribose sugar, a phosphate group, and a nitrogenous base. They are the building blocks of RNA (ribonucleic acid), one of the essential molecules in all living organisms. The nitrogenous bases found in ribonucleotides include adenine, uracil, guanine, and cytosine. These molecules play crucial roles in various biological processes, such as protein synthesis, gene expression, and cellular energy production. Ribonucleotides can also be involved in cell signaling pathways and serve as important cofactors for enzymatic reactions.
Dipeptidyl-Peptidase IV (DPP-4) inhibitors are a class of medications used to treat type 2 diabetes. They work by increasing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), which help regulate blood sugar levels in the body.
Incretin hormones are released from the gut in response to food intake and promote insulin secretion, suppress glucagon secretion, slow down gastric emptying, and reduce appetite. However, these hormones are rapidly degraded by the enzyme DPP-4, which reduces their effectiveness.
DPP-4 inhibitors block the action of this enzyme, thereby increasing the levels of incretin hormones in the body and enhancing their effects on blood sugar control. Some examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin.
These medications are usually taken orally once or twice a day and are often used in combination with other diabetes medications, such as metformin or sulfonylureas, to achieve better blood sugar control. Common side effects of DPP-4 inhibitors include upper respiratory tract infections, headache, and nasopharyngitis (inflammation of the throat and nasal passages).
Adamantane is a chemical compound with the formula C10H16. It is a hydrocarbon that consists of a cage-like structure of carbon atoms, making it one of the simplest diamondoid compounds. The term "adamantane" is also used more broadly to refer to any compound that contains this characteristic carbon cage structure.
In the context of medicine, adamantane derivatives are a class of antiviral drugs that have been used to treat and prevent influenza A infections. These drugs work by binding to the M2 protein of the influenza virus, which is essential for viral replication. By blocking the function of this protein, adamantane derivatives can prevent the virus from multiplying within host cells.
Examples of adamantane derivatives used in medicine include amantadine and rimantadine. These drugs are typically administered orally and have been shown to be effective at reducing the severity and duration of influenza A symptoms, particularly when used early in the course of infection. However, resistance to these drugs has become increasingly common among circulating strains of influenza A virus, which has limited their usefulness in recent years.
Metformin (Glucophage): Type 2 Diabetes
Metformin - Wikipedia
Discontinuing Metformin: The Crowdsourced View
Glyburide and Metformin: MedlinePlus Drug Information
Dementia: Could diabetes drug metformin impact risk?
NDMA Prompts Metformin Recall | MedPage Today
Synjardy (empagliflozin and metformin hydrochloride) | CenterWatch
Metformin: Generic, Side Effects, Dosages, Interactions & Warnings
METFORMIN-GA - MyDr.com.au
Metformin (Oral Route) Proper Use - Mayo Clinic
Dementia and Diabetes: How Metformin Can Impact Risk
Diabetes drug metformin could treat blindness - ScienceBlog.com
DailyMed - METFORMIN HYDROCHLORIDE tablet, extended release
Metformin and diabetes | How to treat diabetes | Diabetes UK
Non-Diabetic Weight Loss With Metformin | livestrong
metformin
Metformin as firstline treatment for type 2 diabetes: are we sure? | The BMJ
Metformin for Multiple Conditions
5 Signs Metformin Is Working For Weight Loss 2023
Metformin | GreenMedInfo | Toxic Ingredient | Natural Medicine
Teva-Metformin - Uses, Side Effects, Interactions - MedBroadcast.com
Metformin xr dosage weight loss